Cargando…

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

BACKGROUND: Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear. METHODS: Patients with metastatic or unresectable UM treated with ipilimuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heppt, Markus V., Amaral, Teresa, Kähler, Katharina C., Heinzerling, Lucie, Hassel, Jessica C., Meissner, Markus, Kreuzberg, Nicole, Loquai, Carmen, Reinhardt, Lydia, Utikal, Jochen, Dabrowski, Evelyn, Gesierich, Anja, Pföhler, Claudia, Terheyden, Patrick, Thoms, Kai-Martin, Zimmer, Lisa, Eigentler, Thomas K., Kirchberger, Michael C., Stege, Henner M., Meier, Friedegund, Schlaak, Max, Berking, Carola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854774/ https://www.ncbi.nlm.nih.gov/pubmed/31722735 http://dx.doi.org/10.1186/s40425-019-0800-0

Ejemplares similares

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
por: Tietze, Julia K., et al.
Publicado: (2018)

Clinical determinants of long-term survival in metastatic uveal melanoma
por: Koch, Elias A. T., et al.
Publicado: (2021)

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
por: Amaral, Teresa, et al.
Publicado: (2020)

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
por: Steeb, Theresa, et al.
Publicado: (2020)

Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument
por: Steeb, Theresa, et al.
Publicado: (2020)

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
por: Salzmann, Martin, et al.
Publicado: (2023)

Assessment of the Quality, Understandability, and Reliability of YouTube Videos as a Source of Information on Basal Cell Carcinoma: Web-Based Analysis
por: Steeb, Theresa, et al.
Publicado: (2022)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

“I Feel I’m in Best Hands with You!”: A Survey of Patient Satisfaction in a German University Skin Cancer Centre
por: STEEB, Theresa, et al.
Publicado: (2021)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
por: Zaremba, Anne, et al.
Publicado: (2021)

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
por: Hecht, Markus, et al.
Publicado: (2018)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study
por: Kirchberger, Michael Constantin, et al.
Publicado: (2023)

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives
por: Heppt, Markus V., et al.
Publicado: (2022)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
por: Becker, Jürgen C., et al.
Publicado: (2017)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments
por: Steeb, Theresa, et al.
Publicado: (2020)

One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website—A Mixed-methods Approach
por: Steeb, Theresa, et al.
Publicado: (2022)

Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey
por: Steeb, Theresa, et al.
Publicado: (2021)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
por: Berking, Carola, et al.
Publicado: (2023)

Willingness to pay for a cure of low-risk melanoma patients in Germany
por: Augustin, Matthias, et al.
Publicado: (2018)

Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019)

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
por: Kähler, Katharina C., et al.
Publicado: (2018)

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
por: Kähler, Katharina C., et al.
Publicado: (2023)

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
por: Lodde, Georg, et al.
Publicado: (2021)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology
por: Reinholz, Markus, et al.
Publicado: (2021)

Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
por: Sadik, Christian D., et al.
Publicado: (2021)

eHealth Literacy in German Skin Cancer Patients
por: Stege, Henner, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_afjvcg9110h9idcmjuj59a4ji3